Division of Cancer Pathobiology News & Announcements

These six Cornerstone stories garnered the most engagements from our CHOP Research Twitter, Facebook, and LinkedIn channels.

Researchers identified aberrant splicing as a culprit behind treatment resistance in B-ALL.

Aberrant splicing leads to downregulation of CD22 in pediatric B-ALL, rendering malignant cells resistant to the effects of CD22-directed immunotherapies.

Oncogenes such as MYC are notorious troublemakers that promote cancer. Previous research strategies have focused on finding ways to quiet down levels of MYC; however, basic scientists at Children’s Hospital of Philadelphia took the opposite approach.

John M. Maris, MD, is leading a pediatric immuno-oncology Center for Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers with support from the NCI Moonshot Initiative.

In this week’s research roundup: personalized gene therapies reach key milestones and scientists probe CAR T-cell resistance.

Vice President Joe Biden’s ambitious “Moonshot” initiative is aimed at boosting and streamlining cancer research across the country. We asked Andrei Thomas-Tikhonenko, PhD, chief of the Division of Cancer Pathobiology and an investigator for the Center for Childhood Cancer…

The Children’s Hospital of Philadelphia Research Institute’s Office of Academic Training and Outreach Programs announced the selection of two new Research Administration fellows. Katherine Yang-Iott and Danika Johnston, PhD.

Colorectal cancer mainly exists in people older than 50, but it also can occur in young adults who have a genetic condition called familial adenomatous polyposis (FAP).